2 Einträge gefunden

1. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

   1. Warren, R B
   2. Carrascosa, J M
   3. Fumero, E
   4. Schoenenberger, A
   5. Lebwohl, M G
   6. Szepietowski, J C
   7. Reich, K

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

   1. Reich, K
   2. Puig, L
   3. Szepietowski, J C
   4. Paul, C
   5. Lacour, J P
   6. Tsianakas, A
   7. Sieder, C

   2020 - Forschungsinformationssystem des UKE